undamentalytics Newsletter

Hedge fund

Caligan Partners LP

13F for June 30, 2026, filed August 14, 2026 · SEC CIK 1727492

Reported value
$2.1bn
100% in companies we cover
Positions we cover
25
Largest LQDA 31.2%
Copy, a year
+42.6%
S&P 500 +20.2%
Copy Sharpe ratio
0.93
S&P 500 1.05

How copying its 13F would have done

$10.0k$20.0k$40.0k 2023202420252026 $34.1k$18.9k
CopyS&P 500 $10,000 copying Caligan Partners LP's filed holdings in companies we cover from May 19, 2023, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −32.3% (S&P 500 −16.9%); beta 1.28; alpha +20.5% a year (t = 0.98); last 12 months +27.7% against +12.1%.

Reported value by quarter

Caligan Partners LP: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $50B $100B $150B Reported value, 2022-12-31: $120.2B Reported value, 2023-03-31: $143.4M Reported value, 2023-06-30: $164.5M Reported value, 2023-09-30: $195.5M Reported value, 2023-12-31: $296.5M Reported value, 2024-03-31: $378.3M Reported value, 2024-06-30: $428M Reported value, 2024-09-30: $315.5M Reported value, 2024-12-31: $394.9M Reported value, 2025-03-31: $479.2M Reported value, 2025-06-30: $515.1M Reported value, 2025-09-30: $720.7M Reported value, 2025-12-31: $1.1B Reported value, 2026-03-31: $1.4B Reported value, 2026-06-30: $2.1B 2022-12-31 2023-09-30 2024-06-30 2025-03-31 2026-06-30 $2.1B
View chart data
Period Reported value
2022-12-31 $120.2B
2023-03-31 $143.4M
2023-06-30 $164.5M
2023-09-30 $195.5M
2023-12-31 $296.5M
2024-03-31 $378.3M
2024-06-30 $428M
2024-09-30 $315.5M
2024-12-31 $394.9M
2025-03-31 $479.2M
2025-06-30 $515.1M
2025-09-30 $720.7M
2025-12-31 $1.1B
2026-03-31 $1.4B
2026-06-30 $2.1B

Latest covered holdings and moves

Covered holdings as of June 30, 2026.

CompanyShare of portfolioValueSharesChange in shares
LQDALiquidia Corp31.23%$647.3m8.12M0.0%
RVMDRevolution Medicines, Inc.17.73%$367.4m1.96M+18.7% Added
ABVXAbivax S.a.10.02%$207.6m1.56M+6.6% Added
PCVXVaxcyte, Inc.6.14%$127.2m2.19M+6.2% Added
EXELExelixis, Inc.4.08%$84.5m1.55M0.0%
TNGXTango Therapeutics, Inc.3.77%$78.2m2.50M+3.8% Added
AVTXAvalo Therapeutics, Inc.2.82%$58.5m3.16M+93.5% Added
XENEXenon Pharmaceuticals Inc.2.59%$53.7m889.9K−36.1% Reduced
ADMAAdma Biologics, Inc.2.31%$47.9m5.73M+20.4% Added
LBRXLB Pharmaceuticals Inc2.25%$46.7m1.44M0.0%
IMCRImmunocore Holdings plc2.12%$43.9m1.38MNew
VRDNViridian Therapeutics, Inc.\de1.94%$40.3m2.19MNew
VORVor Biopharma Inc.1.71%$35.4m1.93M0.0%
SABSSAB Biotherapeutics, Inc.1.50%$31.1m7.97M0.0%
IVAInventiva S.a.1.49%$30.9m8.16M+64.1% Added
AURAAura Biosciences, Inc.1.47%$30.5m4.30M+1769.9% Added
TYRATyra Biosciences, Inc.1.24%$25.8m807.0K−36.8% Reduced
IRDOpus Genetics, Inc.1.21%$25.0m6.08M0.0%
ANIKAnika Therapeutics, Inc.1.01%$21.0m1.44M0.0%
SGMTSagimet Biosciences Inc.0.93%$19.3m2.50MNew
ARTVArtiva Biotherapeutics, Inc.0.81%$16.8m1.74MNew
FTHFaeth Therapeutics, Inc.0.76%$15.7m629.5K+399.6% Added
MBXMBX Biosciences, Inc.0.53%$11.0m200.0K−76.4% Reduced
VRCAVerrica Pharmaceuticals Inc.0.27%$5.7m923.9K0.0%
CLRBCellectar Biosciences, Inc.0.06%$1.3m470.0KNew
CompanyBought (value)Shares
RVMDRevolution Medicines, Inc.$57.9m309.0K
IMCRImmunocore Holdings plc$43.9m1.38M
VRDNViridian Therapeutics, Inc.\de$40.3m2.19M
AURAAura Biosciences, Inc.$28.9m4.07M
AVTXAvalo Therapeutics, Inc.$28.3m1.53M
SGMTSagimet Biosciences Inc.$19.3m2.50M
ARTVArtiva Biotherapeutics, Inc.$16.8m1.74M
ABVXAbivax S.a.$12.8m96.0K
FTHFaeth Therapeutics, Inc.$12.6m503.5K
IVAInventiva S.a.$12.1m3.19M
ADMAAdma Biologics, Inc.$8.1m968.5K
PCVXVaxcyte, Inc.$7.4m127.9K
TNGXTango Therapeutics, Inc.$2.9m91.3K
CLRBCellectar Biosciences, Inc.$1.3m470.0K
IRDOpus Genetics, Inc.$8,4502.1K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
MLYSMineralys Therapeutics, Inc.−$75.1m−2.77M
SYRESpyre Therapeutics, Inc.−$44.3m−878.1K
MBXMBX Biosciences, Inc.−$35.8m−648.6K
XENEXenon Pharmaceuticals Inc.−$30.4m−503.1K
MAZEMaze Therapeutics, Inc.−$18.4m−615.0K
TYRATyra Biosciences, Inc.−$15.0m−470.0K
XLOXilio Therapeutics, Inc.−$942,996−112.1K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
MLYSMineralys Therapeutics, Inc.$75.1m2.77M
SYRESpyre Therapeutics, Inc.$44.3m878.1K
MAZEMaze Therapeutics, Inc.$18.4m615.0K
XLOXilio Therapeutics, Inc.$942,996112.1K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestMay 19, 2023 to November 2, 2026+42.6%+20.2%0.931.05−32.3%1.28
Last three yearsNovember 3, 2023 to November 2, 2026+58.1%+21.8%1.141.16−32.3%1.40
Last yearNovember 7, 2025 to November 2, 2026+26.1%+14.2%0.700.84−32.3%1.43

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.